Twitch Interactive, Inc. has filed a new inter partes review petition at the Patent Trial and Appeal Board, opening IPR2026-00397 on June 29, 2026. As of the initial docket entry, the proceeding is identified under Twitch’s name, but practitioners will want to watch closely for the patent owner, challenged patent number, and petition details as the Board record develops. View full case on Docket Alarm.

Although the early case caption does not yet reveal the full set of underlying merits documents, an IPR filing by a platform like Twitch is immediately notable.

A new inter partes review filed at the Patent Trial and Appeal Board could be one to watch for companies operating at the intersection of life sciences, nutraceuticals, and consumer health. In IPR2026-00400, the proceeding is captioned Thorne Research, Inc. and was filed on June 22, 2026.

At this early stage, the PTAB docket signals that a patent challenge involving Thorne Research is underway, but practitioners should note that key details—including the specific patent claims at issue, the identity of the petitioner and patent owner as reflected in the styled papers, and the precise invalidity combinations asserted—may develop as the record fills out.

A new inter partes review, IPR2026-00376, was filed at the Patent Trial and Appeal Board on June 18, 2026, naming Luxottica of America Inc. in the proceeding. While the publicly available docket caption confirms the PTAB filing and the involvement of Luxottica, this is the kind of early-stage matter patent practitioners will want to watch closely as the petition, patent-at-issue, and asserted invalidity theories come into sharper focus.

At this stage, the key takeaway is that a petitioner has asked the PTAB to institute trial on one or more claims of a patent connected to Luxottica.

ResMed Corp. has been named in a new inter partes review, IPR2026-00341, filed on June 12, 2026, before the Patent Trial and Appeal Board. While the newly filed docket entry identifies the proceeding by the company name, practitioners will want to watch closely as the petition develops and the challenged patent, claims at issue, and prior-art combinations come into sharper focus through the institution briefing.

At this stage, the publicly available case caption signals that a patent associated with ResMed’s portfolio is being challenged at the PTAB.

Tesla Inc. is the named petitioner in a newly filed inter partes review, IPR2026-00382, at the Patent Trial and Appeal Board, adding another matter for practitioners tracking high-stakes validity disputes before the USPTO.

Another PTAB proceeding has been filed against ResMed, with IPR2026-00341 entering the Patent Trial and Appeal Board on June 12, 2026. The petition places one of ResMed’s patents under inter partes review, opening a new front in what could become an important dispute for companies operating in the sleep-disorder and respiratory-device space.

At this stage, the publicly available docket identifies the proceeding by the title Resmed Corp., but practitioners will want to monitor the case record closely as the petition, mandatory notices, and related filings further clarify the specific patent claims at issue, the identity of all real parties in interest, and any parallel district court or ITC litigation that may shape the Board’s discretionary-review analysis.

As with any newly filed IPR, the key issues will center on which patent is being challenged, which claims are targeted, and what prior-art grounds are asserted. Typically, petitioners rely on anticipation and obviousness grounds under 35 U.S.C. §§ 102 and 103, supported by combinations of patents, printed publications, and expert declarations.

A new inter partes review proceeding at the Patent Trial and Appeal Board could draw close attention from patent owners, challengers, and counsel following the medical technology sector. In IPR2026-00341, filed June 12, 2026, the petition is styled Resmed Corp., signaling that ResMed is involved in a fresh PTAB dispute over the validity of an issued patent.

At this early stage, the public docket identifies the proceeding but may not yet fully reflect all underlying petition details, including the specific patent number, all real parties in interest, and the complete list of asserted prior-art grounds.

A new inter partes review, IPR2026-00391, was filed on June 5, 2026, at the Patent Trial and Appeal Board naming Teladoc Health, Inc. in the proceeding. The filing places another spotlight on the digital health and telemedicine patent landscape, where platform functionality, remote care workflows, and software-driven healthcare delivery continue to generate high-stakes validity disputes.

At this early stage, the PTAB docket identifies the proceeding by title but may not yet reflect the full set of publicly available petition details practitioners typically watch for, including the specific patent number, the complete alignment of petitioner and patent owner, and the precise prior-art combinations asserted in the challenge.

A new inter partes review, IPR2026-00387, was filed at the Patent Trial and Appeal Board on June 5, 2026, under the caption Optiver US LLC. At this early stage, the proceeding is notable less for a developed merits record and more for what it signals: another PTAB dispute involving a sophisticated market participant, with the potential to touch on commercially important technology and high-stakes parallel enforcement or licensing issues.

Based on the docket currently available, the proceeding names Optiver US LLC as the petitioner.

Vivint LLC has filed a new petition for inter partes review at the Patent Trial and Appeal Board in IPR2026-00375, opened on June 1, 2026.

A new post-grant review proceeding at the Patent Trial and Appeal Board could be worth watching for companies and counsel operating in competitive consumer product and health-tech markets. In PGR2026-00051, titled Hyper Ice, Inc., a petitioner has asked the PTAB to review the validity of a recently issued patent associated with Hyper Ice, Inc. The petition was filed on May 26, 2026.

At this early stage, the PTAB docket signals the opening of a post-grant challenge, but practitioners should note that post-grant review itself already says a great deal about the patent at issue.

Pinterest, Inc. has filed a new inter partes review petition at the Patent Trial and Appeal Board, opening IPR2026-00366 on May 22, 2026. For patent litigators and in-house IP teams, the filing is worth watching not only for the substantive patentability issues it may raise, but also for what it could signal about Pinterest’s broader litigation and defensive patent strategy.

At this stage, the PTAB docket identifies the proceeding by petitioner name—Pinterest, Inc.—but practitioners should review the underlying petition papers on Docket Alarm for the specific patent number, challenged claims, and real-party-in-interest disclosures as they become available.

Meta Platforms, Inc. has launched a new inter partes review at the Patent Trial and Appeal Board, filing IPR2026-00347 on May 13, 2026. At this stage, the PTAB docket reflects the petition filing, but practitioners should note that early-filed IPRs like this one often become important indicators of broader litigation and licensing strategy, especially when a major technology company is the petitioner.

The proceeding is styled Meta Platforms, Inc., identifying Meta as the challenging party.

Palo Alto Networks, Inc. has filed a new inter partes review petition at the Patent Trial and Appeal Board, opening IPR2026-00362 on May 15, 2026. For patent litigators and in-house IP teams, this is the kind of proceeding worth watching early: even before the Board decides whether to institute review, the petition can offer a detailed roadmap of invalidity theories, claim-prioritization strategy, and the petitioner’s broader litigation posture.

At this stage, the publicly available case caption identifies Palo Alto Networks, Inc. as the petitioner, but the docket summary provided here does not specify the challenged patent number, the patent owner, or the exact unpatentability grounds asserted.

ATT Services, Inc. has launched a new inter partes review at the Patent Trial and Appeal Board, filing IPR2026-00348 on May 5, 2026.